We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.85 | 4.70 | 5.00 | 4.85 | 4.85 | 4.85 | 56,585 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.83M | -2.24M | -0.0042 | -11.55 | 25.87M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/8/2016 12:49 | MW postulates on recent rise.... | birotop | |
12/8/2016 10:26 | The companies balance sheet is changing now and being reflected in the SP, off to 25p with any luck | squiresquire | |
11/8/2016 18:11 | 900,000 trade at 14p | weyweyumfozo | |
11/8/2016 13:45 | I think thats why the price is rising, we are now in the territory of changing between Research and Development into sales and licensing out sales, very nice area to be in when RNSs can make one hell of a difference. Roll on they. | squiresquire | |
11/8/2016 09:15 | I see that there is a four month IHS that has broken out on the above six month line chart. However, it hasn't quite broken out on the candlestick chart, where 13.25p looks like the breakout point. Anyway, the target will be about 18p. A decent RNS would help. | weyweyumfozo | |
10/8/2016 11:47 | I agree that they have made decent progress re getting the approvals. As to when the next news will be, who knows?..... France, well, they don't exactly hurry themselves do they?.....put it this way, I'm not holding my breath! re institutional buying, tend to doubt it, as: 1)Eden to small m.cap for most institutions 2) If it was of interest, the only way institutions can get a decent amount of stock is via a placing. None of the above is to say eden can't make decent progress, but the nematicide deal seems to be a long time in the offing..... | the prophet | |
10/8/2016 11:25 | Prophet Given the wait for the news to start re actually selling product, now EDEN has and now other trials are under way for crops at this moment and given we are waiting for France to agree when other countries within the EU have agreed already to using EDENS treatment, i am thinking France news should come along really soon as the actual growers will want to use it for this season. We should now see a pick up in interest from Institutions in the share given proximity of sales. | squiresquire | |
10/8/2016 10:55 | sp looking good, but not sure re the 'excellent newsflow coming now', be nice to see some of these much vaunted deals come through?...... | the prophet | |
10/8/2016 10:48 | EDEN Starting to move, 25p next step. Excellent newsflow coming now. Since Eden's last AGM, I am pleased to report that, following the initial EU approval by Malta of our agrochemical fungicide product, 3AEY, further approvals have been granted in Italy, Bulgaria, Kenya, Greece and Spain. Already, product sales have been made directly to our partners in Kenya and Greece, with sales to be made this year in Italy and Spain where our partner is manufacturing the product itself. French approval is expected during 2016. Eden has a strong portfolio of products based on the three active substances for which we already have EU approval. We are now able, thanks to the funding received in March 2016, to progress registration of 3AEY and other products in areas such as Australia, USA and South America, where we can leverage the safety and in some cases trial data which we have already generated for the EU approval process. In crop protection, we have a number of well-established partners to sell our products (Sumi Agro France, Sipcam Italia and Iberia and Efthymiadis) with trials on-going with partners for other areas of the world (USA, South America, Australia, Central Europe and North Africa). | squiresquire | |
04/8/2016 17:13 | Eden has a well-balanced portfolio of products, projects and opportunities at differing levels of risk of commercial success, the first of which is now bearing fruit, with a strong pipeline behind it. All part of the process of Eden becoming a truly commercial entity, having shifted from a purely development phase. In the 2015 Annual Report, your CEO said that “the outlook for the Company is better than it has been at any point in the past”. I would like to reiterate his comment and assure you that I will do my best to make sure we capitalise on our position and make Eden the success it should be. | squiresquire | |
04/8/2016 16:17 | One can only hope :-) | speculator59 | |
04/8/2016 15:43 | Buckle up, times are getting good. | squiresquire | |
18/7/2016 15:12 | From AGM three weeks ago, French approval soon along with more dosh, Since Eden’s last AGM, I am pleased to report that, following the initial EU approval by Malta of our agrochemical fungicide product, 3AEY, further approvals have been granted in Italy, Bulgaria, Kenya, Greece and Spain. Already, product sales have been made directly to our partners in Kenya and Greece, with sales to be made this year in Italy and Spain where our partner is manufacturing the product itself. French approval is expected during 2016. Eden has a strong portfolio of products based on the three active substances for which we already have EU approval. We are now able, thanks to the funding received in March 2016, to progress registration of 3AEY and other products in areas such as Australia, USA and South America, where we can leverage the safety and in some cases trial data which we have already generated for the EU approval process. In crop protection, we have a number of well-established partners to sell our products (Sumi Agro France, Sipcam Italia and Iberia and Efthymiadis) with trials on-going with partners for other areas of the world (USA, South America, Australia, Central Europe and North Africa). Eden continues to develop and commercialise, with partners, a range of products using its patented GO-E encapsulation system with terpene technology in agrochemicals and other markets such as human (TerpeneTech for biocide and head-lice applications) and animal health (Bayer Animal Health for animal health products). Some of these opportunities are well advanced, such as Eden’s nematicide product, where formulation work, field trials and testing are complete and arrangements are being concluded with our prospective partner to commercialise this product. Other opportunities are earlier stage concepts where the potential is significant, but the risk of commercial success is higher. Developing products takes time, as does nurturing relationships with any customer, especially the bigger players where just getting a foot in the door can take a lot of time and effort. Field trials have to be conducted, the regulatory requirements have to be checked and met. Distributors and users then have to be convinced that these new products really do work. Then, you can sell products, generate revenues and, ultimately, make profits. Eden has a well-balanced portfolio of products, projects and opportunities at differing levels of risk of commercial success, the first of which is now bearing fruit, with a strong pipeline behind it. All part of the process of Eden becoming a truly commercial entity, having shifted from a purely development phase. In the 2015 Annual Report, your CEO said that “the outlook for the Company is better than it has been at any point in the past”. I would like to reiterate his comment and assure you that I will do my best to make sure we capitalise on our position and make Eden the success it should be. | squiresquire | |
18/7/2016 09:52 | Yes, up 15% quickly this morning after steady rises most days last week. Unable to get a quote at the moment with both Barclays and Hargreaves Lansdown. | redhill9 | |
18/7/2016 09:29 | couple of links showing that Eden's partners are actively promoting 3AEY ( called 3LOGY in Italy or ARAW in Spain) There is a translation facility on you tube, but the English translation leaves something to be desired! Shares moving up nicely now. | the prophet | |
15/7/2016 15:25 | Not surprising considering their current work and new countries to work in, South Africa next, the Botrytis is one hell of a market. | squiresquire | |
15/7/2016 15:13 | Yes, it is recovering nicely. | lr2 | |
15/7/2016 14:48 | Anyway, good to see the share price recovering nicely. | the prophet | |
15/7/2016 14:47 | No idea what you are on about???? This is 'eden' thread?...... | the prophet | |
11/7/2016 09:24 | hxxp://www.edenresea hxxp://www.edenresea | supersonico | |
11/7/2016 08:27 | And still you lot avoid the real questions. How ate they going to boost sales this time round, "sell" another licence to TT ? | quazie12 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions